Price T Rowe Associates Inc Harrow Health, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Harrow Health, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 17,648 shares of HROW stock, worth $688,448. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,648

Previous 17,262 2.24%

Holding current value

$688,448

Previous $361,000 119.94%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$20.85 - $46.47 $8,048 - $17,937	386 Added 2.24%	17,648 $794,000
Q2 2024 Aug 14, 2024	BUY	$10.0 - $21.64 $5,900 - $12,767	590 Added 3.54%	17,262 $361,000
Q1 2024 May 15, 2024	BUY	$9.3 - $13.23 $9,606 - $13,666	1,033 Added 6.61%	16,672 $221,000
Q4 2023 Feb 14, 2024	BUY	$8.1 - $16.36 $12,336 - $24,916	1,523 Added 10.79%	15,639 $176,000
Q3 2023 Nov 14, 2023	BUY	$14.03 - $22.08 $17,439 - $27,445	1,243 Added 9.66%	14,116 $203,000
Q2 2023 Aug 14, 2023	BUY	$17.37 - $28.08 $51,641 - $83,481	2,973 Added 30.03%	12,873 $246,000
Q1 2023 May 15, 2023	SELL	$13.84 - $21.46 $112,104 - $173,826	-8,100 Reduced 45.0%	9,900 $210,000
Q4 2022 Feb 14, 2023	SELL	$10.28 - $14.78 $8,224 - $11,824	-800 Reduced 4.26%	18,000 $266,000
Q3 2022 Nov 14, 2022	BUY	$6.57 - $24.88 $24,309 - $92,056	3,700 Added 24.5%	18,800 $227,000
Q4 2021 Feb 14, 2022	BUY	$8.5 - $12.0 $37,400 - $52,800	4,400 Added 41.12%	15,100 $130,000
Q2 2021 Aug 16, 2021	SELL	$6.68 - $11.07 $10,861 - $17,999	-1,626 Reduced 13.19%	10,700 $99,000
Q1 2021 May 17, 2021	BUY	$6.26 - $11.03 $77,160 - $135,955	12,326 New	12,326 $83,000

Others Institutions Holding HROW

# of Institutions

176

Shares Held

21.4M

Call Options Held

845K

Put Options Held

717K

View Full List

About HARROW HEALTH, INC.

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $1.06B
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

More about HROW

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Harrow Health, Inc. Transaction History